Reference
  1. Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A, et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol. 2012;129:448-455.
  2. De Boissieu D, Dupont C. Sublingual immunotherapy for cow’s milk protein allergy: A preliminary report. Allergy Eur J Allergy Clin Immunol. 2006;61:1238-9.
  3. Scadding GW, Shamji MH, Jacobson MR, et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy. 2010;40:598-606.
  4. Palomares O, Martín-Fontecha M, Lauener R, et al. Regulatory T cells and immune regulation of allergic diseases: Roles of IL-10 and TGF-β. Genes Immun. 2014;15:511-20.
  5. Allam JP, Stojanovski G, Friedrichs N, et al. Distribution of Langerhans cells and mast cells within the human oral mucosa: New application sites of allergens in sublingual immunotherapy? Allergy Eur J Allergy Clin Immunol. 2008;63:720-7.
  6. Wood RA, Kim JS, Lindblad R, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow’s milk allergy. J Allergy Clin Immunol. 2016;137:1103-1110.e11.
  7. Takahashi M, Taniuchi S, Soejima K, er al. Successful desensitization in a boy with severe cow’s milk allergy by a combination therapy using omalizumab and rush oral immunotherapy. Allergy, Asthma Clin Immunol 2015;11:10-2.